Glucuronidation, a common phase II biotransformation reaction, is one of the major and metabolism pathways of xenobiotics. In this process, glucuronic acid is conjugated to a drug or a drug metabolite via a carboxylic acid, a hydroxy, or an amino group to form acyl-, -, and/or -glucuronide metabolites, respectively. This process is traditionally thought to be a detoxification pathway. However, some acyl-glucuronides react with biomolecules , which may result in immune-mediated idiosyncratic drug toxicity (IDT). In order to avoid this, one may attempt in early drug discovery to modify the lead compounds in such a manner that they then have a lower probability of forming reactive acyl-glucuronide metabolites. Because most drugs or drug candidates bear multiple functionalities, e.g., hydroxy, amino, and carboxylic acid groups, glucuronidation can occur at any of those. However, differentiation of isomeric acyl-, , and -glucuronide derivatives of drugs is challenging. In this study, gas-phase ion-molecule reactions between deprotonated glucuronide metabolites and BF followed by collision-activated dissociation (CAD) in a linear quadrupole ion trap mass spectrometer were demonstrated to enable the differentiation of acyl-, , and -glucuronides. Only deprotonated -glucuronides and deprotonated, migrated acyl-glucuronides form the two diagnostic product ions: a BF adduct that has lost two HF molecules, [M - H + BF - 2HF], and an adduct formed with two BF molecules that has lost three HF molecules, [M - H + 2BF - 3HF]. These product ions were not observed for deprotonated -glucuronides and unmigrated, deprotonated acyl-glucuronides. Upon CAD of the [M - H + 2BF - 3HF] product ion, a diagnostic fragment ion is formed via the loss of 2-fluoro-1,3,2-dioxaborale (MW of 88 Da) only in the case of deprotonated, migrated acyl-glucuronides. Therefore, this method can be used to unambiguously differentiate acyl-, , and -glucuronides. Further, coupling this methodology with HPLC enables the differentiation of unmigrated 1-β-acyl-glucuronides from the isomeric acyl-glucuronides formed upon acyl migration. Quantum chemical calculations at the M06-2X/6-311++G(d,p) level of theory were employed to probe the mechanisms of the reactions of interest.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.analchem.9b02717DOI Listing

Publication Analysis

Top Keywords

acyl- -glucuronide
8
gas-phase ion-molecule
8
ion-molecule reactions
8
collision-activated dissociation
8
carboxylic acid
8
hydroxy amino
8
acyl- -glucuronides
8
-glucuronides deprotonated
8
deprotonated -glucuronides
8
deprotonated migrated
8

Similar Publications

Exploring the Impact of Pharmaceutical Excipient PEG400 on the Pharmacokinetics of Mycophenolic Acid Through In Vitro and In Vivo Experiments.

Int J Mol Sci

December 2024

State Key Laboratory of Functions and Applications of Medicinal Plants, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang 550025, China.

Mycophenolic acid (MPA) is a commonly used immunosuppressant. In the human body, MPA is metabolized into mycophenolic acid 7-O-glucuronide (MPAG) and mycophenolic acid acyl-glucuronide (AcMPAG) mainly through liver glucuronidation, which involves UDP-glucuronosyltransferase (UGTs) and transfer proteins. Research has indicated that the pharmaceutical excipient PEG400 can impact drug processes in the body, potentially affecting the pharmacokinetics of MPA.

View Article and Find Full Text PDF

Gastroprotective Effect of Hexanic Extract of Against Ethanol-Induced Gastric Lesions in a CD1 Mouse Model.

Plants (Basel)

December 2024

Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, Colonia Casco de Santo Tomás, Miguel Hidalgo, Mexico City 11340, Mexico.

Peptic ulcers result from an imbalance between protective factors (e.g., prostaglandins, nitric oxide, and sulfhydryl groups) and aggressive risk factors (e.

View Article and Find Full Text PDF

Bempedoic acid is a new drug that improves the control of cholesterol levels, either as monotherapy or in combination with existing lipid-lowering therapies, and shows clinical efficacy in cardiovascular disease patients. Thus, patients with comorbidities and under multiple therapies may be eligible for bempedoic acid, thus facing the potential problem of drug-drug interactions (DDIs). Bempedoic acid is a prodrug administered orally at a fixed daily dose of 180 mg.

View Article and Find Full Text PDF

Candesartan Has No Clinically Meaningful Effect on the Plasma Concentrations of Cytochrome P450 2C8 Substrate Repaglinide in Humans.

Drug Metab Dispos

November 2024

Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland (M.O.W.P., K.C., A.T.); Bioanalytical Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland (M.T.E.); Unit of Clinical Pharmacology, Turku University Hospital, Turku, Finland (M.O.W.P., K.C., A.T.); Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland and Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland (M.Ne., M.Ni., J.T.B.); Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark and Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark (T.K.B.); Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland (M.Ni., J.T.B.); and Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland (A.M.F.)

In vitro evidence shows that the acyl--D-glucuronide metabolite of candesartan inhibits cytochrome P450 (CYP) 2C8 with an inhibition constant of 7.12 M. We investigated the effect of candesartan on the plasma concentrations and glucose-lowering effect of repaglinide, a sensitive clinical CYP2C8 index substrate.

View Article and Find Full Text PDF

Two trials were performed to evaluate the effect of renal and hepatic impairment on the pharmacokinetics of pritelivir and its metabolites. The renal impairment trial included subjects with mild, moderate, and severe impairment, while the hepatic impairment trial included subjects with moderate impairment. Both trials recruited a matched control group of healthy subjects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!